YM 58483 (BTP2): Selective SOCE Blocker for Immune and Fibrosis Studies

Executive Summary: YM 58483 (BTP2) is a highly selective inhibitor of store-operated calcium entry (SOCE) channels, including CRAC and TRP channels (product info). This compound demonstrates potent suppression of T cell activation and interleukin-2 (IL-2) production, with IC₅₀ values in the nanomolar range. In vivo, YM 58483 attenuates fibrosis and restores salivary gland function after irradiation by inhibiting the ORAI2/JNK/NFAT1/TGF-β1 signaling axis (DOI). The specificity of YM 58483 for SOCE channels enables mechanistic studies in both immune modulation and fibrotic disease models. APExBIO supplies YM 58483 as a solid compound suitable for both in vitro and in vivo research (B7542 kit).

Biological Rationale

Store-operated calcium entry (SOCE) is essential for sustained Ca²⁺ influx in non-excitable cells, including lymphocytes, macrophages, basophils, dendritic cells, and mast cells. SOCE is primarily mediated by CRAC channels (notably ORAI1 and ORAI2) and non-selective TRP channels. Calcium influx through these channels is a pivotal event for immune cell activation, cytokine secretion, and fibrogenic responses (DOI). Dysregulation of SOCE contributes to aberrant T cell responses and tissue fibrosis. Recent evidence highlights the ORAI2-mediated SOCE pathway as a critical driver of early-stage postirradiation salivary gland fibrosis, acting through a JNK/NFAT1/TGF-β1 axis (internal article).

Mechanism of Action of YM 58483 (BTP2), a store-operated Ca²⁺ entry (SOCE) blocker

YM 58483 (BTP2) is a synthetic small molecule that selectively inhibits SOCE channels. Its primary targets are CRAC channels (ORAI1, ORAI2) and TRP channels, which mediate Ca²⁺ influx following depletion of endoplasmic reticulum (ER) Ca²⁺ stores. YM 58483 binds to and blocks these channels, preventing the rise in intracellular Ca²⁺ that is necessary for downstream signaling (product info). This blockade suppresses T cell receptor-induced NFAT activation and IL-2 gene transcription, leading to potent inhibition of T cell effector functions. In fibrosis models, YM 58483 interrupts the ORAI2/JNK/NFAT1/TGF-β1 axis, thus attenuating profibrotic signaling and tissue remodeling (DOI).

Evidence & Benchmarks

• YM 58483 inhibits PHA-induced IL-2 production in T cells with an IC₅₀ of ~17 nM, demonstrating high potency in immune assays (product info).
• Pharmacological blockade of SOCE using YM 58483 significantly reduces fibrosis markers and restores salivary gland function to 84.61% of normal in irradiated mouse models (DOI).
• YM 58483 selectively inhibits NFAT-driven promoter activity but does not affect AP-1-driven pathways, confirming mechanistic specificity (product info).
• In vivo use of YM 58483 in mouse models suppresses donor anti-host cytotoxic T cell activity and IFN-γ production, supporting its immunomodulatory effects (internal article).
• Recent studies map the ORAI2/JNK/NFAT1/TGF-β1 signaling axis as the critical pathway modulated by YM 58483 in radiation-induced fibrosis (DOI).

This article extends the findings in "ORAI2-Mediated SOCE Drives Early Salivary Gland Fibrosis Post-IR" by providing quantitative benchmarks for YM 58483 efficacy and clarifying its mechanism in immune and fibrotic contexts. It also updates "YM 58483 (BTP2): Applied SOCE Blockade in Fibrosis Research" by detailing recent in vivo outcomes and IC₅₀ values.

Applications, Limits & Misconceptions

• YM 58483 is validated as a tool compound for dissecting SOCE-dependent signaling in T cell activation assays and fibrosis models.
• The compound is also used in mechanistic studies of immune modulation and has potential applications in preclinical models of bronchial asthma and other inflammatory diseases (product info).
• Its specificity for SOCE channels enables selective inhibition without significant off-target effects at recommended concentrations (DOI).

Common Pitfalls or Misconceptions

• YM 58483 does not inhibit voltage-gated calcium channels or ligand-gated channels; its action is limited to SOCE mechanisms.
• It is not a general immunosuppressant; efficacy is context-dependent and requires functional SOCE pathway components.
• YM 58483 is insoluble in water, requiring ethanol or DMSO for solution preparation at ≥50 mg/mL and ≥90 mg/mL, respectively (product info).
• Long-term storage of solutions is not recommended; fresh preparation is advised due to compound stability constraints.
• Results from murine models may not directly extrapolate to humans without further translational studies.

Workflow Integration & Parameters

Protocol Parameters

• Compound preparation: Dissolve YM 58483 in ethanol (≥50 mg/mL) or DMSO (≥90 mg/mL); avoid aqueous solutions due to insolubility (product info).
• Storage: Store solid at -20°C; use stock solutions promptly after preparation.
• In vitro T cell activation assay: Typical working concentrations range from 10–100 nM; IC₅₀ for IL-2 inhibition is ~17 nM.
• In vivo fibrosis models: Administer YM 58483 at doses validated in literature (e.g., 0.5–1.0 mg/kg i.p. daily for 30 days in mouse irradiation models) (DOI).
• Readouts: Quantify IL-2 production via ELISA and fibrosis markers (e.g., TGF-β1 expression, collagen deposition) using histology and qPCR.

Conclusion & Outlook

YM 58483 (BTP2) is a high-affinity, selective SOCE inhibitor with robust preclinical validation for immune modulation and antifibrotic intervention. Its ability to block the ORAI2/JNK/NFAT1/TGF-β1 axis in radiation-induced salivary gland fibrosis models positions it as a valuable tool for mechanistic dissection and therapeutic exploration (DOI). The compound's precise targeting, as supplied by APExBIO, supports reproducible research in both cellular and animal models. Ongoing studies will clarify its translational potential for addressing tissue fibrosis and immune dysregulation in clinical settings.